ArticlebioRxiv : the preprint server for biology2025
3D imaging with superior resolution using Atacama Clear.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
3-dimensional (3D) imaging is a powerful tool for interrogation of intact tissues, but can suffer from poor resolution due to impediments such as high tissue autofluorescence that remains a significant challenge in imaging cleared samples, including human clinical specimens. We developed Atacama Clear (ATC), a 3D imaging technology that increases signal-to-noise ratios (SNRs) while simultaneously augmenting the capacity of tissue to be cleared. ATC exhibited SNRs that are up to 200% of widely used 3D imaging methods, potentiated all tested optical clearing solutions by up to 600%, decreased the time of optical clearing by up to a factor of 8, and enabled detection of poorly recognized antigens with a remarkable 4-fold increase in signal detection while using up to 10-fold lower antibody concentrations. Strikingly, ATC produced up to a 5x increase in transgenic fluorescent reporter protein signal detection, which is instead often diminished with currently used 3D imaging methods. This increased imaging efficacy enabled multiplex interrogation of tough fibrous tissue and specimens that naturally exhibit high levels of background noise, including the heart, kidney, and human biopsies. Indeed, ATC facilitated the use of AI based auto-segmentation with simple low tech stereo fluorescence microscopy, visualization of previously undocumented adjacent nephron segments that exhibit notoriously high autofluorescence, elements of the cardiac conduction system, and distinct human glomerular tissue layers, with cellular resolution. Taken together, these studies establish ATC as a platform for complex 3D imaging studies of basic and clinical specimens with superior resolution.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.